Hot flashes
Drug research and approvals for hot flashes: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 33 studies of hot flashes are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 33
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 33 recruiting on ClinicalTrials.gov ↗- Effects of a Dietary Supplement in Women With Late Perimenopause or Early PostmenopauseNCT07863973 · Not applicable · University of Alicante · starts Nov 1, 2026
- Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal WomenNCT07751029 · Not applicable · Spectrum Clinical Research, LLC · starts Oct 26, 2026
- A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through MenopauseNCT07829653 · Phase 3 · Astellas Pharma Inc · starts Oct 23, 2026
- Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot FlashesNCT07729150 · Not applicable · Dana-Farber Cancer Institute · starts Oct 1, 2026
- Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)NCT07834463 · Not applicable · India Glycols Ltd · starts Sep 1, 2026
- Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving…NCT07594002 · Not applicable · University of Kentucky · starts Aug 13, 2026
- A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms…NCT07535541 · Not applicable · University of Virginia · starts May 21, 2026
- Effects of a Dietary Intervention Based on the Dietary Guidelines for the Brazilian Population on the Reduction of…NCT07822230 · Not applicable · Federal University of Health Science of Porto Alegre · starts May 6, 2026
- Thermoregulatory Physiology of Menopausal Hot FlashesNCT07824648 · Not applicable · SRI International · starts May 5, 2026
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityNCT07218445 · Phase 4 · Mayo Clinic · starts Apr 8, 2026
Drug Pipeline
2 approved, 13 in phase 3, 8 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Fezolinetant, Veralipride
- Gabapentin
- Phase 3 Voltage-gated calcium channel modulator
- Elinzanetant
- Phase 3 Neurokinin 1 receptor antagonist
- Medroxyprogesterone acetate
- Phase 3 Progesterone receptor agonist
- Paroxetine
- Phase 3 Serotonin transporter inhibitor
- Venlafaxine
- Phase 3 Serotonin transporter inhibitor
- Estrogens, conjugated
- Phase 3 Estrogen receptor agonist
- Citalopram
- Phase 3 Serotonin transporter inhibitor
- Desvenlafaxine
- Phase 3 Serotonin transporter inhibitor
- Tamoxifen
- Phase 3 Estrogen receptor alpha modulator
- Filgrastim
- Phase 3 Granulocyte colony stimulating factor receptor agonist
- Megestrol acetate
- Phase 3 Progesterone receptor agonist
- Cefepime
- Phase 3 Bacterial penicillin-binding protein inhibitor
- Levofloxacin anhydrous
- Phase 3 DNA gyrase inhibitor
- Elacestrant
- Phase 2 Estrogen receptor alpha degrader
- MF101
- Phase 2 Estrogen receptor beta agonist
- Nitroglycerin
- Phase 2 Soluble guanylate cyclase activator
- Prasterone
- Phase 2 Unknown
- Elismetrep
- Phase 2 Transient receptor potential cation channel subfamily M member 8 inhibitor
- Methionine
- Phase 2
- Toluene
- Phase 2
- PD-0299685
- Phase 2
- Melatonin
- Phase 1 Melatonin receptor agonist
- Norleucine
- Phase 1
- Estetrol anhydrous
- Phase 1 Estrogen receptor agonist
- Bupivacaine
- Early phase 1 Sodium channel protein type IV alpha subunit blocker
How Its Trials Ended
246 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 88 whose ending is known, 57% met their primary endpoint, 13% missed it and 31% stopped early.
- Completed, result not reported10442%
- Met its primary endpoint5020%
- Ongoing3313%
- Status unknown219%
- Missed its primary endpoint114%
- Stopped: enrollment or feasibility114%
- Stopped: other or unclear114%
- Stopped: safety21%
- Stopped: sponsor or business decision21%
- Stopped: lack of efficacy10%
Medicines Authorised in the EU
Newest firstCondition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA